Core Viewpoint - The company anticipates a significant decline in net profit for the fiscal year 2025, projecting a decrease of 63.26% to 72.13% compared to the previous year, primarily due to non-recurring gains and market pressures [2][4]. Group 1: Performance Forecast - The performance forecast applies to a scenario where the company achieves profitability but experiences a net profit decline of over 50% compared to the same period last year [2]. - For the fiscal year 2025, the company expects a net profit attributable to shareholders of the parent company to be between 110 million and 145 million yuan, representing a year-on-year decrease of 24.962 million to 28.462 million yuan [4]. - The forecasted net profit, excluding non-recurring gains and losses, is expected to be between 80 million and 118 million yuan, reflecting a year-on-year decrease of 9.058 million to 12.858 million yuan [4]. Group 2: Previous Year’s Performance and Financial Status - In the previous year, the total profit was 433.9014 million yuan, with a net profit attributable to shareholders of the parent company at 394.6157 million yuan [6]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was 208.5835 million yuan, with earnings per share at 0.44 yuan [6]. Group 3: Reasons for Performance Decline - The decline in performance is primarily attributed to the impact of non-recurring gains from the previous year, where significant asset disposal gains were realized due to the completion of land transfer procedures [6]. - Market factors such as reduced product demand, intense industry competition, and price reductions from national procurement policies have pressured overall industry profits, leading to a decline in revenue and gross profit for the company [6]. - Strategic investments in high-quality development and increased R&D expenditures for innovative drugs and high-end formulations have also contributed to short-term cost pressures affecting profits [6].

Core Viewpoint - Lu Kang Pharmaceutical (600789) expects a significant decrease in net profit for 2025, projecting a range of 110 million to 145 million yuan, representing a year-on-year decline of 63.26% to 72.13% [1] Financial Performance - The anticipated decrease in profit is primarily attributed to the impact of non-recurring gains and losses, market factors, and short-term cost pressures related to strategic investments [1] - The previous year's performance was boosted by substantial asset disposal gains from the completion of land transfer procedures, leading to significant fluctuations in this year's results [1] Industry Context - The pharmaceutical industry is facing overall profit pressure due to slowing product market demand, intense competition, and price reductions from national centralized procurement policies [1] - Traditional human formulation products are experiencing significant changes in terminal demand, leading to pressures on volume and pricing adjustments, which have negatively impacted revenue and gross profit [1] Strategic Investments - To promote high-quality development, the company is increasing its investment in research and development, focusing on innovative drugs, high-end formulations, and synthetic biology [1] - The increase in amortization expenses related to previously approved technical assets and the sustained high level of R&D investment are expected to have a short-term negative impact on profits [1]